Search - tctmd.com

Displaying 521 - 540 of 809

Sort: Relevancy | Date

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

News Daily News

Merck Calls Quits on CETP Inhibitor Anacetrapib

Michael O'Riordan

October 12, 2017

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Todd Neale

September 22, 2017

News Daily News

New Performance and Quality Metrics for STEMI and NSTEMI Care

Michael O'Riordan

September 21, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Daily News

Dust From World Trade Center Attacks Linked to Higher Lipid Levels in Children

Yael L. Maxwell

September 13, 2017

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

PURE Investigators: Rethink Diet Guidance to Plug More Fats, Fewer Carbs

Shelley Wood

August 29, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Industry News

AUM Cardiovascular Receives FDA Approval For Revolutionary Diagnostic Heart Device

August 08, 2017

Advertisement

Statins and Diabetes: Causal Link Reinforced in New Analysis

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Merck Calls Quits on CETP Inhibitor Anacetrapib

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

New Performance and Quality Metrics for STEMI and NSTEMI Care

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Dust From World Trade Center Attacks Linked to Higher Lipid Levels in Children

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

PURE Investigators: Rethink Diet Guidance to Plug More Fats, Fewer Carbs

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

ESC Updates Guidelines for Treating STEMI Patients

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Evolocumab Not Cost-Effective at Current List Price

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

AUM Cardiovascular Receives FDA Approval For Revolutionary Diagnostic Heart Device

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content